STAT3 and cardiac hypertrophy: Transgenic overexpression of STAT3 in cardiomyocytes results in cardiac hypertrophy but confers protection from cardiomyopathy in response to doxorubicin [10] whereas loss of STAT3 causes dilated cardiomyopathy in aged mice and exacerbates doxorubicin-induced cardiotoxicity [70].